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Breast cancer is the most common malignancy among women in
the Western world. In many instances, breast cancer at diagnosis is
a systemic disease that consequently requires adjuvant therapy
with hormones or cytotoxic drugs. One important determinant of
breast cancer growth and development is tumour cell sensitivity to
cytotoxic agents that are given during initial treatment, either as
induction chemotherapy or as adjuvant treatment to locoregional
therapy. The occurrence of resistance of tumours to chemotherapy
is one of the main obstacles to the successful chemotherapeutic
treatment of cancer. Thus, factors which may increase sensitivity
of tumours to anti-cancer drugs would increase survival of
patients.
Experimental studies indicated that several fatty acids may
modulate the sensitivity of tumour cells to several cytotoxic drugs.
In vitro studies showed that sensitivity of mammary tumour cells
to the cytotoxic drugs doxorubicin and mitoxantrone was
increased by some polyunsaturated fatty acids (PUFA) supple-
mented in the medium and/or integrated into membrane phospho-
lipids (Burns and Spector, 1994). Among long-chain PUFA, fatty
acids of the n-3 series, and specifically docosahexaenoic acid
(DHA, 22:6n-3), have been reported to increase the cytotoxic effi-
cacy of doxorubicin on L1210 murine leukaemia cells (Guffy et al,
1984), on small-cell lung carcinoma cell lines (Zijlstra et al, 1987),
and on a breast cancer cell line (Germain et al, 1998). Besides 
cell cultures, dietary fatty acids also influenced sensitivity of
mammary tumours to several cytotoxic drugs in experimental
animals. In a model of transplantable human mammary carcinoma
in athymic mice, dietary fish oil enriched in n-3 PUFA has been
found to enhance efficacy of anti-cancer drugs doxorubicin
(Borgeson et al, 1989), cyclophosphamide (Shao et al, 1997) and
mitomycin C (Borgeson et al, 1989; Shao et al, 1995).
Although experimental observations suggested that PUFA, and
particularly n-3 PUFA, increased the sensitivity of mammary
tumour cells to several anti-cancer drugs, no data in humans is
available concerning the potential influence of dietary fatty acids
on the chemosensitivity of tumours to cytotoxic drugs. However,
circumstantial evidence suggests that a phenomenon similar to
those revealed in experimental studies may operate in humans. In
breast cancer patients who had undergone treatment, estimated
dietary total fat and saturated fat were associated with risk for
treatment failure in a subpopulation of patients with oestrogen
receptor-rich tumours, suggesting that dietary fatty acids may
affect the response of breast cancer to treatment (Holm et al,
1993). In a previous study, we found that a decreased level of
alpha-linolenic acid (essential fatty acid of the n-3 family, 18:3 
n-3) in adipose tissue of breast cancer patients was associated with
subsequent development of visceral metastases (Bougnoux et al,
1994). These data suggest that the type of fatty acids available to
tumour cells may have influenced the outcome of breast cancer by
altering the response of cancer cells to the initial treatment.
To obtain direct evidence of an association between PUFA and
tumour response to chemotherapy, we have prospectively exam-
ined the association between the level of individual fatty acids in
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Tours, Francethe adipose breast tissue, used as an indicator of stored fatty acids,
and the response of the breast tumour to primary (neoadjuvant)
chemotherapy in 56 patients with locally advanced breast carci-
noma. We found that a high level of docosahexaenoic acid 
(22:6 n-3, DHA) in breast adipose tissue was related to the
response of the primary tumour to neoadjuvant chemotherapy,
whereas a low level of DHA was associated to no response or even
to tumour growth. This observation suggests that n-3 fatty acids
available to the tumour may modulate in vivo the response of the
tumour to the cytotoxic agents used.
SUBJECTS AND METHODS
Characteristics of patients and disease
Fifty-six patients with histologically confirmed, non-metastatic
invasive breast carcinoma were entered into the study between
September 1987 and February 1992 when the following criteria
were met: a specimen of adipose tissue had been obtained during
surgery; pathology, staging (TNM) and treatment had been
performed at the University Hospital of Tours; and follow-up had
been expected to be possible. Mean age of patients was 51.7 years
(range 25–69). Distribution of patients according to age,
menopause and body mass index (BMI) is presented in Table 1.
All patients had their medical history recorded and complete
clinical examination by a gynaecological surgeon and a radiation
oncologist. Chest radiograph, liver and cardiac ultrasound exami-
nation, isotope bone scan, as well as any additional investigation
required were performed to assess the extent of disease. All
patients had basal biological assessment (haematology, liver and
kidneys, and serum tumour markers).
Tumour size was evaluated before surgery by clinical examina-
tion and mammographic assessment of tumour diameters,
according to the World Health Organization (WHO) recommenda-
tions (Miller et al, 1981). Mean tumour size was determined by
measuring the product of the two largest diameters (Tonkin et al,
1985). Surgical biopsy was performed before chemotherapy for
pathological diagnosis and tissue markers assays.
The pathological characteristics of the tumours were reviewed
by a single pathologist. Histopathological types were defined
according to the WHO classification (Types histologiques des
tumeurs du sein, Organisation Mondiale de la Santé; classification
histologique internationale des tumeurs no. 2, 1981, Genève). All
tumours were carcinoma, with 44 tumours belonging to the ductal
type, six to the lobular, and six tumours to undetermined or to
other types. Histoprognostic grading (SBR grade) was based on
the evaluation of mitosis, tubular formation and nuclear pleo-
morphism, according to Bloom and Richardson (1957). Vascular
invasion was defined by presence of tumour cells within lumen of
blood or lymph vessels. Oestrogen and progesterone receptors
were measured in tumour cytosol with an immunoenzymoassay
(Abbott, USA).
Primary chemotherapy
The combination of drugs used as primary chemotherapy was
mitoxantrone (12 mg m–2) by bolus injection (b.i.) on day 1 and on
days 1 and 8, an administration of vindesine (2 mg m–2) (b.i.),
cyclophosphamide (500 mg m–2) and 5-fluorouracile (700 mg m–2)
by short infusion. The cycle was repeated starting on day 29. Nine
first patients were given a regimen in which epirubicin, 25 mg m–2
(b.i.) on days 1 and 8, replaced mitoxantrone. All patients
completed three cycles within the time frame scheduled. There
was no acute toxicity of grade greater than 3 according to WHO
grading. No patients received hormonal therapy simultaneously
with primary chemotherapy.
Anti-tumour end point of chemotherapy
To evaluate the chemosensitivity of tumours, tumour response was
assessed after completion of three cycles of primary chemotherapy
by both a surgical and a medical oncologist on the basis of the
reduction in the product of the two largest diameters obtained
through clinical and mammographic reassessment. Complete
response (CR) was defined by complete disappearance of all
evidence of tumour. Partial response (PR) was defined by at least
50% reduction in the products of largest diameters. Stable disease
(SD) was defined as less than 50% reduction but no more than
25% increase in the products of largest diameters, and progressive
disease (PD) as greater than 25% increase. When tumour regres-
sion was 50% or less, a mastectomy was performed, followed by
radiation therapy using modalities reported elsewhere (Calais et al,
1994) and by six additional cycles of chemotherapy. When regres-
sion was greater than 50%, local treatment was radiation alone by
external radiotherapy and interstitial implant as a boost to the
initial location of the tumour, followed by six additional cycles of
chemotherapy.
Adipose tissue preparation and fatty acids analysis
Adipose tissue was obtained during biopsy, freed from epithelial
breast or carcinoma tissue, washed in saline and kept frozen in
liquid nitrogen until analysis. Laboratory analyses were blinded on
the links between samples and disease status of subjects (tumour
response). The procedures for preparation of fatty acids have been
reported elsewhere (Bougnoux et al, 1994). In summary, total
lipids of the adipose tissue were extracted and triglycerides puri-
fied on silica gel G thin-layer chromatographic plates. Fatty acids
were analysed as methyl esters by gas chromatography on a fused-
silica capillary column with a liquid phase of carbowax 20 M,
using an on-column injector and a flame ionization detector. Fatty
acids were identified and quantified with the use of commercial
standards (Nu-Check-Prep, Elisian, MN, USA). Fatty acids were
expressed as percentage of total fatty acids area. Unidentified
peaks amounted for less than 3%. All solvents were high-
performance liquid chromatography (HPLC) grade, and nitrogen
was used at each step to protect PUFA from peroxidation. Intra-
and interassay coefficients of variation (CV) have been already
reported in detail (Chajès et al, 1992). CV were less than 1% for
large peaks and reached 10% for the smallest peaks.
Statistical analysis
Data were analysed using the EPI-INFO and BMDP statistical
software. Associations between fatty acids taken either individu-
ally or as nutritional classes and clinical characteristics of the
patients were assessed by the Kruskall–Wallis non-parametric test.
All variables associated with response to chemotherapy were
assessed by unconditional logistic regression with BMDP software
(Dixon, 1985).
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Description of patients
Among the 56 patients studied, 26 (47%) displayed a complete
(five) or partial (21) response to chemotherapy, whereas progres-
sive disease occurred in one. Chemosensitivity was not signifi-
cantly associated with any clinical factors, although a trend was
observed for an inverse association of tumour size (clinical or
mammographic) to response of tumours to chemotherapy (Table 1).
Relationship between adipose tissue fatty acid levels
and tumour chemosensitivity
Mean levels of individual fatty acids were compared according to
tumour response, or not, to chemotherapy (Table 2). Levels of total 
n-3 PUFA taken as a family of polyunsaturated fatty acids was higher
in the group of patients with an objective (CR or PR > 50%) response
to chemotherapy than in patients with no response (SD or PD)
(P= 0.004). Among n-3 PUFA, only an elevated 22:6n-3 level
was significantly associated with an objective response to chemo-
therapy (P= 0.005). Breast adipose tissue levels of total saturates,
monounsaturates, or n-6 PUFA were similar between patients with a
response and patients with no response to chemotherapy.
Relationship between adipose tissue fatty acid levels
and characteristics of patients and disease
Levels of total n-3 PUFA, or levels of 22:6 n-3 in adipose breast
tissue, were found to be significantly higher in patients ³50 years
old (P< 0.001, P< 0.01 respectively) or in post-menopause 
(P< 0.01, P< 0.05 respectively). Level of 22:6n-3 was also higher
in patients with BMI ³25.0 (P< 0.05). No significant association
was found between n-3 PUFA and any of the other clinical factors
(data not shown).
Multivariate analysis
To control for these possible confounding factors, a logistic regres-
sion analysis was performed. The following continuous variables
were entered into the models: age, BMI, mammographic size,
adipose tissue level of n-3 PUFA or 22:6n-3.
The 22:6n-3 level proved to be an independent predictor for
response to chemotherapy (P= 0.03, likelihood ratio test). When
22:6n-3 was categorized into two classes, using the median value
(0.15%) as a threshold, we found that the risk of tumour response to
chemotherapy was multiplied by 4.6 when the 22:6n-3 level was
above the median value (Table 3). When the n-3 PUFA level was
adjusted for the three potential confounding factors, the association
between this group of fatty acids and tumour response to
chemotherapy did not reach a significant level; the risk of response
to chemotherapy was 3.2 times higher when the n-3 PUFA level was
above the median value (0.78%), used as a threshold, compared with
when the level was below the median value (Table 3).
DISCUSSION
The purpose of this study was to determine whether the response
of breast carcinoma to anti-cancer drugs might be influenced by
the type of fatty acids available to the tumour. To examine this
hypothesis, we have prospectively studied the association between
the level of individual fatty acids in the adipose breast tissue, used
as an indicator of stored fatty acids, and the response of the tumour
to primary (neoadjuvant) chemotherapy in 56 patients with local-
ized breast carcinoma. Breast cancer patients presenting with oper-
able breast tumour larger than 3cm and undergoing primary
chemotherapy as the first step in their treatment represent an
appropriate and simple system for evaluating the influence of host
parameters on chemosensitivity of their tumour because tumour
size is readily measurable and adipose tissue contiguous to the
tumour is readily available during diagnosis procedures. We found
an association of elevated DHA level in the adipose breast tissue
with chemosensitivity of the breast tumour. We observed that the
degree of tumour shrinkage after primary chemotherapy was
highest in patients with elevated levels of DHA in breast adipose
tissue. Although n-3 PUFA content of adipose tissue increased
with age, menopause and BMI, DHA proved to be an independent
predictive factor of tumour chemosensitivity. This predictive value
of adipose breast tissue DHA levels on tumour chemosensitivity is
unique because no host-dependent parameter has been available
for predicting the probability of tumour response to anti-cancer
agents. These data suggest that n-3 PUFA available to the tumour
may modulate the tumour response to chemotherapy in humans.
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Table 1Clinical characteristics of patients and breast tumours and
response to chemotherapy
Clinical factor Number of Objective responsea P-valueb
patients to chemotherapy (%)
Age
< 50 26 35
³50 30 57 NSc
Menopausal status
Premenopausal 30 47
Post-menopausal 26 50 NS
Body mass index
< 25 26 39
³25 30 53 NS
Tumour clinical size
≤50mm 25 60
> 50mm 31 36 0.06
Tumour mammographic size
≤50mm 41 54
> 50mm 15 27 0.07
Nodal statusd
Negative 24 54
Positive 32 41 NS
Histoprognostic gradee
I or II 35 43
III 21 52 NS
Vascular invasionf
Absent 32 41
Present 22 50 NS
Oestrogen receptor
> 10fmol mg–1 45 47
≤10fmol mg–1 11 46 NS
Progesterone receptor
> 10fmol mg–1 37 54
≤10fmol mg–1 19 32 NS
aCR or PR (>50%). bChi-squared test. cNot significant. dClinical staging.
eScarff and Bloom. fUnavailable for two patients.Tumour mass results from several components involved in
tumour growth. These include tumour cell proliferation, as well as
tumour cell loss (Steel, 1979). Experimental data from animal
studies suggest that dietary n-3 PUFA (originating from marine
oils) inhibit mammary tumour growth by increasing tumour cell
loss (Gabor and Abraham, 1986; Gonzalez et al, 1991, 1993). In
our study, no link was observed between the mitotic index found in
the carcinoma and any individual fatty acid measured in the
adipose tissue (data not shown). Therefore, the association found
between elevated long-chain n-3 PUFA and reduction in the size of
the tumour, after chemotherapy, suggests that these fatty acids may
increase the tumour cell loss component of the tumour rather than
decrease cell proliferation in response to chemotherapy.
The association of chemosensitivity of breast carcinoma with an
elevated level of n-3 PUFA, particularly DHA, in adipose breast
tissue can be interpreted in different ways. The first possible inter-
pretation is that n-3 PUFA available to the tumour influenced
chemosensitivity through an alteration of the physical state of
tumour cell membranes. We previously reported that membrane
fatty acids of breast carcinoma result from intrinsic properties of the
tumour and also from host fatty acids available to the tumour
(Chajès et al, 1995a). Therefore, if we assume that patients with
elevated levels of DHA in their adipose breast tissue have elevated
levels of this fatty acid in membrane phospholipids of their breast
tumour, this biochemical change would result in an increase in
tumour cell membrane fluidity, an event which has been linked with
chemosensitivity (Siegfried et al, 1983; Burns and Spector, 1994).
Putative mechanisms due to an increase in membrane fluidity of
tumour cells may involve an increased passive diffusion of cyto-
toxic drugs (Pelletier et al, 1990), resulting in an intracellular accu-
mulation of drugs (Burns et al, 1998; Callaghan et al, 1993).
An alternative interpretation is that n-3 PUFA available to the
tumour may modulate chemosensitivity of breast carcinoma
through an increased formation of peroxides in the tumour. In
mammary tumour cells in vitro (Chajès et al, 1995b) or in human
breast cancer cells growing in nude mice (Gonzalez et al, 1991,
1993), supplementation of medium or diet with n-3 PUFA led to
an increase in lipid peroxidation products in tumour cells and to a
suppression of breast cancer growth, suggesting that PUFA may
interfere with tumour cell growth through lipid peroxides forma-
tion. In human mammary carcinoma grafted to nude mice, the
activities of some enzymes involved in the oxidative stress were
increased by feeding high levels of corn oil, enriched in n-6 PUFA
(Shao et al, 1994), or menhaden oil, enriched in n-3 PUFA (Shao
et al, 1995), resulting in an enhanced antineoplastic effect of the
drug mitomycin C. Some experimental studies evaluated whether
lipid peroxidation products from PUFA in tumour cells would
correlate with the sensitivity of tumour cells to cytotoxic drugs. In
mammary tumour cells in vitro, we found that various n-6 or n-3
PUFA combined with a pro-oxidant mixture (sodium ascorbate/2-
methyl-1,4-naphthoquinone) increased both cytotoxic efficacy of
the anti-cancer drug doxorubicin and level of peroxides in tumour
cells, with the strongest effects obtained with DHA (Germain et al,
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Table 2 Fatty acids in adipose breast tissue according to tumour response to primary chemotherapy
Fatty acid (%)a No response Objective response P-valueb
(SD + PD) (CR + PR > 50%)
(n = 30) (n = 26)
Mean Mean
Saturates
16:0 (palmitic acid) 23.27 22.76 NSc
18:0 (stearic acid) 5.78 5.52 NS
Total saturatesd 32.95 32.08 NS
Monounsaturates
16:1 (palmitoleic acid) 3.75 3.76 NS
18:1 (oleic acid) 42.45 42.24 NS
Total monounsaturatese 47.44 47.40 NS
Polyunsaturates n-6
18:2 n-6 (linoleic acid) 14.90 15.24 NS
20: 4 n-6 (arachidonic acid) 0.33 0.40 0.07
22:4 n-6 (adrenic acid) 0.18 0.22 NS
Total n-6f 15.92 16.39 NS
Polyunsaturates n-3
18:3 n-3 (a-linolenic acid) 0.38 0.44 NS
22:5 n-3 (docosapentaenoic acid) 0.21 0.26 0.06
22:6 n-3 (docosahexaenoic acid, DHA) 0.14 0.20 0.005
Total n-3 0.73 0.90 0.004
aPercentage of total fatty acids. bKruskal–Wallis test. cNot significant (P ³ 0.10). dIncluded: 14:0, 15:0, 17:0, 20:0, 22:0, 24:0. eIncluded: 14:1, 20:1,
22:1. fIncluded: 18:3 n-6, 20:2 n-6, 20:3 n-6. 
Table 3 Predictive value of docosahexaenoic acid on tumour response to
chemotherapy, adjusted for age, body mass index and tumour size
Variable Adjusted 95% CI P-valueb
odds ratioa
Docosahexaenoic acid (22:6 n-3)
< 0.15% 1
>0.15% 4.6 1.2–18.5 0.03
Polyunsaturated fatty acids (n-3 PUFA)
<  0.87% 1
> 0.87% 3.2 0.8–12.6 0.10
aUnconditional logistic regression. bLikelihood ratio test; %, median value.1998). In a similar way, in implanted human breast tumours in
mice, the use of fish oil and pro-oxidant iron supplemented with
the drug edelfosine resulted in an increase in both the level of lipid
peroxidation products in tumours and the cytotoxic efficacy of the
drug (Hardman et al, 1997). In our study, we found that, among all
PUFAs measured in adipose tissue, DHA, the most unsaturated
fatty acid and therefore a good substrate for peroxidation, was
related to the highest tumour shrinkage subsequent to the action of
cytotoxic drugs. This observation may suggest that a higher level
of DHA in adipose tissue could increase the cytotoxic efficacy of
drugs on breast carcinoma by providing a higher availability in the
substrate for peroxides formation.
The exact mechanism by which lipid peroxides may modulate
tumour sensitivity to cytotoxic drugs remains to be elucidated. Free
radicals and peroxides formed during lipid peroxidation may
physically damage cellular proteins, DNA (Masotti et al, 1988) and
lipid membranes including those of mitochondria, which are a key
target for chemotherapy-induced apoptosis (Decaudin et al, 1998).
Insights gained into mechanisms involved in the sensitivity of
tumours to anti-cancer agents are likely to lead to new strategies in
the treatment of cancer. If certain fatty acids available to the
tumour, particularly 22:6n-3, appear to increase the response of
tumours to chemotherapy, the next question is which factors might
influence DHA levels in breast adipose tissue in breast cancer
patients. DHA levels in adipose tissue have been shown to reflect
long-term dietary intake of estimated n-3 PUFA or fish intake
(London et al, 1991), and an enrichment in the diet of breast cancer
patients with n-3 PUFA led to increased levels of DHA in breast
adipose tissue (Bagga et al, 1997). Thus, dietary intervention could
provide an effective means of increasing DHA availability in
tumour tissues and thereby may affect chemosensitivity of
tumours. We are currently investigating the mode of action of
dietary n-3 fatty acids on the chemosensitivity of mammary
tumours in a rodent experimental system.
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